BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, placebo of bezafibrate
APHP180668
Phase 3 small_molecule active
Quick answer
BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée, placebo of bezafibrate for primary sclerosing cholangitis is a Phase 3 program (small_molecule) at Pari Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Pari Pharma GmbH
- Indication
- primary sclerosing cholangitis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active